English
Choose your country/region and language
Your experience may change as only information for the country or region you select will be presented.
Access Beta-Amyloid 1-42 (RUO) Immunoassay
Amyloid beta 1-42 (Aβ1-42) is a 42-amino acid peptide that is a major component of the amyloid plaques found in the brains of individuals with Alzheimer's disease (AD). It is produced from the amyloid precursor protein (APP) through the action of secretases. Aβ1-42 is known to be more prone to aggregation than other forms of amyloid beta, such as Aβ1-40, and this aggregation is believed to play a key role in the pathology of AD.
Aβ1-42 is extensively studied in AD research to understand its neurotoxicity and aggregation. Compared with Aβ1-40, Aβ1-42 is more hydrophobic and prone to self-aggregation, forming oligomeric and fibrillar species that deposit as amyloid plaques in the brain. These aggregates are implicated in synaptic dysfunction, neuroinflammation, and neuronal loss, central to the pathogenesis of Alzheimer’s disease.
Request more info
Our Aβ1-42 assay
µL sample volume
%CV
pg/mL limit of detection
All
Amyloid beta
Accumulation of Aβ1-42 in the brain is a primary pathological hallmark of AD. Elevated Aβ1-42 levels can serve as a biomarker for disease onset and progression.
Aß in Alzheimer’s disease research
Aβ1-42 is extensively studied in AD research. Some research focuses on understanding Aβ1-42's neurotoxicity, often linked to oxidative stress and aggregation into toxic tangles and plaques. Other studies are involved in determining effectiveness of anti-amyloid treatments.
Assay Characteristics
The following results are derived from internal studies and are intended solely for informational purposes. These findings are not intended to serve as official specifications or guarantees of performance.
Assay Characteristic |
Access Amyloid-ß (RUO) |
| Assay format | Two+-step sandwich |
| Recommended sample type(s) | Plasma (K2-EDTA) |
| Unit of measure | pg/mL |
| Analytical Measuring Range | 0.2 – 250 pg/mL |
| Open Reagent pack stability | 2 to 10 °C for 31 days |
| Open Calibrator pack stability | 2 to 10 °C for 31 days |
| Open QC vial stability | 2 to 10 °C for 31 days |
| Sample volume (uptake) | 105 µL |
| Time to first result (approximate) | 30 minutes |
| Imprecision (%CV) Within-Laboratory | ~3.6 – 4.9% |
We are committed to research that advances neurodegenerative disease diagnostics to make them more accessible to people around the world. Leveraging our history of IVD development, we are empowering cutting-edge research with high-quality, innovative assays that deliver accurate and affordable testing solutions at scale. Learn more about our comprehensive solutions.
Amyloid beta and Alzheimer’s disease
Lower levels of plasma Aß1-42, a fragment of the amyloid precursor protein, correlate with brain amyloidosis, indicating the presence and progression of amyloid plaques in the brain, which has implications for AD pathology.
Understanding Aß1-42 levels may help to further research into AD pathology.
Join us in learning more about
Aß1-42 in AD pathology
Thank you for your request.
A Beckman Coulter representative will contact you shortly.
2025-14771
